Get the Stockscreener App
69.97
1.14%
-0.81
After Hours:
69.97
Nuvalent Inc stock is traded at $69.97, with a volume of 1.06M.
It is down -1.14% in the last 24 hours and down -9.14% over the past month.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
See More
Previous Close:
$70.78
Open:
$70.83
24h Volume:
1.06M
Relative Volume:
1.91
Market Cap:
$5.01B
Revenue:
-
Net Income/Loss:
$-224.29M
P/E Ratio:
-17.94
EPS:
-3.9
Net Cash Flow:
$-185.06M
1W Performance:
+8.15%
1M Performance:
-9.14%
6M Performance:
-33.24%
1Y Performance:
+8.06%
1-Day Range:
$68.76
$72.18
1-Week Range:
$58.05
$72.18
52-Week Range:
$55.53
$113.51
Nuvalent Inc Stock (NUVL) Company Profile
Name
Nuvalent Inc
Sector
Industry
Phone
508-446-2272
Address
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
69.97 | 5.01B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.89 | 124.91B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
549.28 | 60.05B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
587.59 | 35.88B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
230.50 | 29.83B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
228.14 | 24.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-14-25 | Upgrade | UBS | Neutral → Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Oct-24-24 | Initiated | UBS | Neutral |
| Aug-29-24 | Initiated | Barclays | Overweight |
| Apr-17-24 | Initiated | Jefferies | Buy |
| Apr-01-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-28-24 | Resumed | Guggenheim | Buy |
| Feb-23-24 | Initiated | Robert W. Baird | Outperform |
| Sep-27-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-24-23 | Initiated | Guggenheim | Buy |
| Jan-18-23 | Initiated | Wedbush | Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
View All
Nuvalent Inc Stock (NUVL) Latest News
Alliancebernstein L.P. Purchases 500 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Commonwealth Equity Services LLC Raises Holdings in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Sei Investments Co. Reduces Stock Position in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent: Cannot Make Sense Of The Valuation - Seeking Alpha
Nuvalent stock touches 52-week low at $61.75 amid market shifts By Investing.com - Investing.com South Africa
Nuvalent stock touches 52-week low at $61.75 amid market shifts - Investing.com Australia
Norges Bank Invests $24.95 Million in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
KLP Kapitalforvaltning AS Buys New Shares in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
What to Expect at AACR 2025: Nuvalent to present Data on Neladalkib and Zidesamtinib - Onco'Zine
Commit To Purchase Nuvalent At $55, Earn 11.9% Annualized Using Options - Nasdaq
(NUVL) On The My Stocks Page - news.stocktradersdaily.com
Is Nuvalent (NUVL) the Best Debt Free Mid Cap Stock to Buy Now? - Yahoo
Nuvalent to Participate in the Stifel 2025 Virtual Targeted Oncology Forum - Quantisnow
Exclusive: Nuvalent CEO to Share Latest Cancer Treatment Innovation Strategy at Stifel Forum - Stock Titan
Nuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Nuvalent, Inc. (NASDAQ:NUVL) Stake Cut by Virtu Financial LLC - MarketBeat
Teacher Retirement System of Texas Boosts Holdings in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Why Nuvalent (NUVL) Is Among the Best Mid Cap Biotech Stocks to Buy - Insider Monkey
Nuvalent chief development officer sells shares worth $292,468 By Investing.com - Investing.com Philippines
10 Best Debt Free Mid Cap Stocks to Buy Now - Insider Monkey
Nuvalent chief development officer sells shares worth $292,468 - Investing.com India
10 Best Mid Cap Biotech Stocks to Buy - Insider Monkey
Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025 - Nasdaq
Breakthrough Cancer Drug Data: New Brain-Penetrant Therapy Shows Promise Against Resistant Tumors - Stock Titan
Connor Clark & Lunn Investment Management Ltd. Sells 18,609 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - MarketBeat
How the (NUVL) price action is used to our Advantage - news.stocktradersdaily.com
Raymond James Financial Inc. Acquires Shares of 133,964 Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent CEO Porter sells $2.05 million in stock By Investing.com - Investing.com Australia
Nuvalent CEO Porter sells $2.05 million in stock - Investing.com
Victory Capital Management Inc. Cuts Stock Position in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Charles Schwab Investment Management Inc. Buys 7,742 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
US Bancorp DE Invests $90,000 in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Bank of New York Mellon Corp Increases Holdings in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
UBS Upgrades Nuvalent (NUVL) - Nasdaq
Nuvalent upgraded to Buy from Neutral at UBS - TipRanks
UBS Upgrades Nuvalent to Buy From Neutral, Maintains $100 Price Target -March 14, 2025 at 07:24 am EDT - Marketscreener.com
Principal Financial Group Inc. Cuts Position in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
HC Wainwright Has Negative Forecast for Nuvalent Q1 Earnings - Defense World
Nuvalent’s (NUVL) Buy Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright maintains Buy on Nuvalent stock, $110 target By Investing.com - Investing.com Canada
New York State Common Retirement Fund Sells 2,495 Shares of Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Where are the Opportunities in (NUVL) - news.stocktradersdaily.com
Rhumbline Advisers Has $3.95 Million Stake in Nuvalent, Inc. (NASDAQ:NUVL) - Defense World
Nuvalent’s Strategic Advances in NSCLC Trials Justify Buy Rating - TipRanks
Nuvalent to Participate in Upcoming March Investor Conferences - Citizentribune
Nuvalent, Inc. Reports 2024 Financial Results and Pipeline Progress - TipRanks
Nuvalent Outlines Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2024 Financial Results - The Malaysian Reserve
Nuvalent's Q4 Net Loss Widens -February 27, 2025 at 07:14 am EST - Marketscreener.com
Earnings Flash (NUVL) Nuvalent Posts Q4 Net Loss $1.05 a Share, vs. FactSet Est of $1.08 Loss - Marketscreener.com
Nuvalent, Inc. SEC 10-K Report - TradingView
Nuvalent Inc Stock (NUVL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.21%
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):